Get With the Guidelines Atrial Fibrillation Registry

Atrial Fibrillation Clinical Trial

— GWTG-AF  

Official title:

Get With the Guidelines-Atrial Fibrillation

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06245187
• Other study ID #: 002
• Status: Recruiting
• Start date: January 2013
• Est. completion date: January 2040

Study information

• Verified date: January 2024
• Source: American Heart Association
• Contact: Kelly Burlison, MPH
• Phone: 214-706-2237
• Email: kelly.burlison[@]heart.org
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

Get With The Guidelines-Atrial Fibrillation is designed to assist hospital care teams in consistently providing the latest evidence-based treatment for their AFib patients. At the same time, it offers a means of monitoring the quality of AFib care in U.S. hospitals and building a database for continued research and further quality improvement.

Description:

Get With The Guidelines-Atrial Fibrillation was initiated in 2013 with over 88 U.S. hospitals participating is designed to assist hospital care teams in consistently providing the latest evidence-based treatment for their AFib patients. At the same time, it offers a means of monitoring the quality of AFib care in U.S. hospitals and building a database for continued research and further quality improvement.

Achievement measures tracked through Get With The Guidelines-Atrial Fibrillation:

1. ACEI/ARB at discharge for LVSD

2. Assessment of thromboembolic risk factors

3. Beta Blocker at discharge

4. Discharged on FDA-approved anticoagulation therapy

5. PT/INR planned follow-up

6. Statin at discharge in AF patients with CAD, CVA/TIA or PVD.

Quality measures tracked through Get With The Guidelines-Atrial Fibrillation:

1. Aldosterone antagonist at discharge

2. Atrial fibrillation patient education

3. Anticoagulation therapy education

4. CHA2DS2-VASC reported

5. Discharge heart rate <110bpm

6. Smoking cessation

7. Warfarin at discharge for valvular atrial fibrillation

Additional measures collected by Get With The Guidelines-Atrial Fibrillation can be viewed at: http://www.heart.org/idc/groups/heart-public/@private/@wcm/@hcm/@gwtg/documents/downloadable/ ucm_451183.pdf

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 17198
• Est. completion date: January 2040
• Est. primary completion date: January 2040
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 125 Years

Eligibility

Inclusion Criteria:

• Patients hospitalized with nonvalvular Atrial Fibrillation or Atrial Flutter

Exclusion Criteria:

• Patients who do not have nonvalvular Atrial Fibrillation or Atrial Flutter

• Patients under 18 years of age

• Patients not admitted as inpatients.

• Patients on comfort care only

• Patients discharged to hospice.

Related Conditions & MeSH terms

• Atrial Fibrillation
• Atrial Flutter

Intervention

Other:
• GWTG Atrial Fibrillation program
Evidence based recommended therapies and counseling prior to hospital discharge.

Locations

Country	Name	City	State
United States	Kelly Burlison	Dallas	Texas

Sponsors (1)

Lead Sponsor	Collaborator
American Heart Association

Country where clinical trial is conducted

United States, 

References & Publications (1)

January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, Conti JB, Ellinor PT, Ezekowitz MD, Field ME, Murray KT, Sacco RL, Stevenson WG, Tchou PJ, Tracy CM, Yancy CW; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014 Dec 2;64(21):e1-76. doi: 10.1016/j.jacc.2014.03.022. Epub 2014 Mar 28. No abstract available. Erratum In: J Am Coll Cardiol. 2014 Dec 2;64(21):2305-7. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Cardiac Tamponade and/or Pericardiocentesis Following Ablation	Percent of patients with cardiac tamponade and/or pericardiocentesis occurring within 30 days following ablation procedure.	30 days